• 1
    Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med 2012; 271: 11121.
  • 2
    Drabovich AP, Pavlou MP, Dimitromanolakis A, Diamandis EP. Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay. Mol Cell Proteomics 2012; 11, April 25 [Epub ahead of print].
  • 3
    Drabovich AP, Jarvi K, Diamandis EP. Verification of male infertility biomarkers in seminal plasma by multiplex selected reaction monitoring assay. Mol Cell Proteomics 2011; 10: M110.004127.
  • 4
    Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG/L. J Urol 1997; 157: 9138.
  • 5
    Kulasingam V, Smith CR, Batruch I, Buckler A, Jeffrey DA, Diamandis EP. “Product ion monitoring” assay for prostate-specific antigen in serum using a linear ion-trap. J Proteome Res 2008; 7: 6407.
  • 6
    Lopez MF, Rezai T, Sarracino DA et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 2010; 56: 28190.